
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 29, 2023

Lexicon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

000-30111
(Commission File Number)

76-0474169
(I.R.S. Employer
Identification Number)

2445 Technology Forest Blvd., 11th Floor
The Woodlands, Texas 77381
(Address of principal executive offices and Zip Code)

(281) 863-3000
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	LXRX	The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01 Entry into a Material Definitive Agreement

On December 29, 2023, Lexicon and one of its subsidiaries entered into a fourth amendment (the “[Fourth Amendment](#)”) to its loan and security agreement (the “[Loan Agreement](#)”) with Oxford Finance LLC and the lenders listed therein. Under the terms of the Fourth Amendment, the existing financial covenants relating to net sales of INPEFA® (sotagliflozin) and minimum cash balance requirements were each modified, with the financial covenant relating to minimum cash balance requirements becoming immediately effective rather than upon Lexicon’s exercise of its option to fund the fourth tranche and following its funding.

Such fourth tranche, under which \$25 million was previously available for draw at Lexicon’s option between December 1 and December 31, 2023, will now be available upon the achievement of specified INPEFA net sales and until April 15, 2025.

Lexicon may not extend the initial 36-month interest-only period to 48 months at its option as previously contemplated.

The foregoing summary does not purport to be complete and is qualified in its entirety by the Fourth Amendment, a copy of which is attached to this report as Exhibit 10.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
*†10.1	— Fourth Amendment to Loan and Security Agreement, dated December 29, 2023, with Oxford Finance, LLC and the lenders listed therein
EX-104	— Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

† In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by “[**]”) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Lexicon Pharmaceuticals, Inc.

Date: December 29, 2023

By: /s/ Brian T. Crum

Brian T. Crum

Senior Vice President and General Counsel

[**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT

This Fourth Amendment to Loan and Security Agreement (this “**Amendment**”) is entered into as of December 29, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders a party hereto from time to time including OXFORD FINANCE CREDIT FUND II, LP, by its manager Oxford Finance Advisors, LLC (“**Credit Fund II**”), OXFORD FINANCE CREDIT FUND III, LP, by its manager Oxford Finance Advisors, LLC (“**Credit Fund III**”), OXFORD FINANCE FUNDING IX, LLC (“**Funding IX**”), OXFORD FINANCE FUNDING XIII, LLC (“**Funding XIII**”), and OXFORD FINANCE FUNDING 2023-1, LLC (“**Funding 2023-1**”; together with Credit Fund II, Credit Fund III, Funding IX, and Funding XIII, each a “**Lender**” and collectively, the “**Lenders**”), LEXICON PHARMACEUTICALS, INC. (“**Parent**”) and LEXICON PHARMACEUTICALS (NEW JERSEY), INC. (“**Lex-NJ**”), each a Delaware corporation with offices located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, TX 77381 (Parent and Lex-NJ, individually and collectively, jointly and severally, “**Borrower**”).

RECITALS

WHEREAS, Collateral Agent, Borrower and the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender have entered into that certain Loan and Security Agreement, dated as of March 17, 2022 (as amended, supplemented or otherwise modified from time to time, collectively, the “**Loan Agreement**”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and

WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:

1. Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.

2. Section 13.1 of the Loan Agreement hereby is amended to insert the following defined term in appropriate alphabetical order:

“**Fourth Amendment Effective Date**” means December 29, 2023.

3. The following defined terms in Section 13.1 of the Loan Agreement hereby are amended and restated in their entireties to read as follows:

“**Amortization Date**” is May 1, 2025.

“**Fourth Draw Period**” is, the period commencing on the date Borrower has received (a) Inpefa FDA Approval and (b) actual trailing six (6) month Inpefa net

product revenue (excluding any collaboration or royalty revenue) of at least [**] and ending on the earliest of (i) the occurrence of an Event of Default; (ii) thirty (30) days after the commencement of the draw period; and (iii) April 15, 2025. As of the Fourth Amendment Effective Date, Lenders acknowledge Borrower's receipt of Inpefa FDA Approval.

4. The following terms in Section 13.1 of the Loan Agreement hereby are deleted in their entirety from wherever they may appear in the Loan Agreement: "First Minimum Cash Test Date"; "Minimum Cash Deferral Milestone 1"; "Minimum Cash Deferral Milestone 2".

5. All uses of the term, "Sotagliflozin" hereby are replaced with the term "Inpefa" wherever they may appear in the Loan Agreement.

6. Section 13.1 of the Loan Agreement hereby is amended to move the following defined terms in appropriate alphabetical order:

"Inpefa FDA Approval" means the FDA's approval of the Inpefa NDA for an indication that is no narrower in scope than the Heart Failure Indication plus heart failure in adult patients without type 2 diabetes (that, for clarity, shall include reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in two populations: (i) adults with heart failure and (ii) adults with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors); written evidence of which must be provided to, reviewed and approved in writing by Collateral Agent.

"Inpefa NDA Milestone" means the FDA's acceptance of Borrower's planned resubmission of the Inpefa NDA for an indication that is no narrower in scope than to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with Type-2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction (the **"Heart Failure Indication"**); written evidence of which must be provided to, reviewed and approved in writing by Collateral Agent.

7. Section 2.2(b) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

"(b) Repayment. Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal (in accordance with the applicable repayment schedule described in clause (3) below), together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender's Term Loan, (2) the effective rate of interest, as determined pursuant to Section 2.3(a), and (3) a repayment amortization schedule equal to twenty-three (23) months, in the amounts set forth in Schedule 2.2(b) hereto. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d)."

8. Section 2.5(f) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

“(f) Unused Fee. A fee, payable to Lenders in full immediately upon the expiration of the Fourth Draw Period, in an amount equal to [**], if the Fourth Draw Period expires and Borrower has not drawn the full amount of the Term D Loan (such fee, the “**Unused Fee**”).”

9. Section 6.10 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

“**6.10 Financial Covenants.**

(a) Minimum T6M Net Product Revenue. As of the last day of each fiscal quarter beginning with the fiscal quarter ending March 31, 2024, Borrower shall achieve actual trailing six (6) month Inpefa net product revenue (excluding any collaboration or royalty revenue) (“**Inpefa NPR**”), of at least the amount set forth in the projections attached hereto as Annex X to Exhibit C for such quarter; provided that, once Borrower achieves trailing twelve (12) month Inpefa NPR of [**] or greater as of the last day of a fiscal quarter ending after the Fourth Amendment Effective Date, Borrower shall, as of the last day of each fiscal quarter thereafter, and in lieu of the requirements otherwise set forth in this Section 6.10(a), achieve trailing twelve (12) month Inpefa NPR of at least [**].

(b) Minimum Cash. From and after the Fourth Amendment Effective Date, until Borrower achieves trailing twelve (12) month Inpefa NPR of at least One Hundred Million Dollars (\$100,000,000.00) (such period, the “**Minimum Cash Period**”), Borrower shall maintain minimum unrestricted cash, cash equivalents and short-term investments of at least Ten Million Dollars (\$10,000,000.00) in Collateral Accounts subject to Control Agreements in favor of Collateral Agent; provided, however, if any Term D Loan is funded, such amount shall be at least Twenty Five Million Dollars (\$25,000,000.00), in either case measured as of the last day of each fiscal quarter beginning with the fiscal quarter ending on December 31, 2023 and continuing as of the last day of each fiscal quarter during the Minimum Cash Period.”

10. Exhibit C to the Loan Agreement hereby is replaced in its entirety with Exhibit C attached hereto.

11. Limitation of Amendment.

- a. The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.
- b. This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.

12. To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

- a. Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;
- b. Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;
- c. The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;
- d. The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;
- e. The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made and filings required to perfect the security interest of the Collateral Agent in the Collateral; and
- f. This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors' rights.

13. Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment.

14. As a condition to the effectiveness of this Amendment, Collateral Agent shall have received, in form and substance satisfactory to Collateral Agent, the following:

- a. this Amendment, duly executed by Borrower;
- b. resolutions, duly adopted by Borrower's board of directors authorizing the entry in to and performance of this Amendment;
- c. an amendment fee equal to [**], which may be debited (or ACH'd) from the Designated Deposit Account in accordance with the Loan Agreement;
- d. all reasonable Lenders' Expenses incurred through the date of this Amendment, which may be debited (or ACH'd) from the Designated Deposit Account in accordance with the Loan Agreement; and
- e. such other documents, and completion of such other matters, as Collateral Agent may reasonably deem necessary or appropriate.

15. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.

16. Section 11 of the Loan Agreement (Choice of Law, Venue and Jury Trial Waiver) is incorporated herein by this reference as though set forth in full.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Loan Agreement to be executed as of the date first set forth above.

BORROWER:

LEXICON PHARMACEUTICALS, INC.

LEXICON PHARMACEUTICALS, INC.

By: _____

Name: Jeffrey L. Wade

Title: President and Chief Financial Officer

LEXICON PHARMACEUTICALS (NEW JERSEY), INC.

By: _____

Name: Jeffrey L. Wade

Title: President and Chief Financial Officer

LEXICON PHARMACEUTICALS (NEW JERSEY), INC.

By: _____

Name: Jeffrey L. Wade

Title: President and Chief Financial Officer

[Signatures continued, next page]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Loan Agreement to be executed as of the date first set forth above.

COLLATERAL AGENT

OXFORD FINANCE LLC

By: _____
Name: Colette H. Featherly
Title: Senior Vice President

LENDERS:

OXFORD FINANCE FUNDING I, LLC
OXFORD FINANCE FUNDING IX, LLC
OXFORD FINANCE FUNDING XIII, LLC
OXFORD FINANCE FUNDING TRUST 2023-1 LLC

By: _____
Name: Colette H. Featherly
Title: Secretary

OXFORD FINANCE CREDIT FUND II LP
By: Oxford Finance, Advisors, LLC
Its: Manager

By: _____
Name: Colette H. Featherly
Title: Senior Vice President

OXFORD FINANCE CREDIT FUND III LP
By: Oxford Finance, Advisors, LLC
Its: Manager

By: _____
Name: Colette H. Featherly
Title: Senior Vice President

[Signature Page to Fourth Amendment to Loan and Security Agreement]

Exhibit C

Compliance Certificate

TO: OXFORD FINANCE LLC, as Collateral Agent and Lender OXFORD FINANCE CREDIT FUND III, LP, as Lender

FROM: LEXICON PHARMACEUTICALS, INC.,
for itself and on behalf of each Borrower

The undersigned authorized officer (“**Officer**”) of LEXICON PHARMACEUTICALS, INC. (for itself and on behalf of each Borrower party to the Loan Agreement (as defined below), “**Borrower**”), hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the “**Loan Agreement**,” capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement),

(a) Borrower is in complete compliance for the period ending _____ with all required covenants except as noted below;

(b) There are no Events of Default, except as noted below;

(c) Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material respects on this date and for the period described in (a), above; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.

(d) Borrower, and each of Borrower’s Subsidiaries, has timely filed all required tax returns and reports, Borrower, and each of Borrower’s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Loan Agreement;

(e) No Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders.

Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements.

Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under “Complies” column.

	Reporting Covenant	Requirement	Actual	Complies		
1)	Financial statements	Quarterly within 45 days		Yes	No	N/A
2)	Annual (CPA Audited) statements	Within 90 days after FYE		Yes	No	N/A
3)	Annual Financial Projections/Budget (prepared on a monthly basis)	Annually (within 45 days of FYE), and when revised		Yes	No	N/A
4)	A/R & A/P agings	If applicable		Yes	No	N/A
5)	8-K, 10-K and 10-Q Filings	If applicable, within 5 days of filing		Yes	No	N/A
6)	Compliance Certificate	Quarterly within 45 days		Yes	No	N/A
7)	IP Report	When required		Yes	No	N/A
8)	Total amount of Borrower’s cash and cash equivalents at the last day of the measurement period		\$_____	Yes	No	N/A
9)	Total amount of Borrower’s Subsidiaries’ cash and cash equivalents at the last day of the measurement period		\$_____	Yes	No	N/A
10)	Total amount of cash and other assets maintained at Lion as of the last day of the measurement period	Total amount not to exceed \$10,000 at any time per Section 7.12 of the Loan Agreement	\$_____	Yes	No	N/A
11)	Total amount of Investments made by Borrower in Lion during the current fiscal year as of the last day of the measurement period	Total amount not to exceed \$10,000 in any fiscal year per Permitted Investments (k)(ii) of the Loan Agreement	\$_____	Yes	No	N/A

Deposit and Securities Accounts

(Please list all accounts; attach separate sheet if additional space needed)

	Institution Name	Account Number	New Account?		Account Control Agreement in place?	
1)			Yes	No	Yes	No
2)			Yes	No	Yes	No
3)			Yes	No	Yes	No
4)			Yes	No	Yes	No

Financial Covenants

	Covenant	Requirement	Actual	Compliance	
1)	Minimum Net Product Revenue (trailing 6 months or (if applicable) 12 months)	See Section 6.10(a); Annex X	_____	Yes	No
2)	Minimum Cash (during Minimum Cash Period)	See Section 6.10(b); \$10MM/\$25MM	_____	Yes	No

Other Matters

- | | | | |
|----|--|-----|----|
| 1) | Have there been any changes in management since the last Compliance Certificate? | Yes | No |
| 2) | Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement? | Yes | No |
| 3) | Have there been any new or pending claims or causes of action against Borrower that involve more than Five Hundred Thousand Dollars (\$500,000.00)? | Yes | No |
| 4) | Have there been any material amendments of or other material changes to the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this Compliance Certificate. | Yes | No |

Exceptions

Please explain any exceptions with respect to the certification above: (If no exceptions exist, state "No exceptions." Attach separate sheet if additional space needed.)

LEXICON PHARMACEUTICALS, INC., for itself and on behalf of each Borrower

By
Name:
Title:

Date:

LENDER USE ONLY

Received by: _____ Date: _____

Verified by: _____ Date: _____

Compliance Status: Yes No

ANNEX X

(Projected Net Product Revenue)

[**]